Frovatriptan indications and usage

Revision as of 22:28, 9 February 2014 by Gerald Chi (talk | contribs)
Jump to navigation Jump to search
Frovatriptan
FROVA® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Frovatriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Indications and Usage

FROVA is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

  • Use only if a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with FROVA, reconsider the diagnosis of migraine before FROVA is administered to treat any subsequent attacks.
  • FROVA is not indicated for the prevention of migraine attacks.
  • Safety and effectiveness of FROVA have not been established for cluster headache.[1]

References

  1. "FROVA (FROVATRIPTAN SUCCINATE) TABLET, FILM COATED [ENDO PHARMACEUTICALS INC.]".

Adapted from the FDA Package Insert.